Aranesp is the trade name for Darbepoetin alfa, a synthetic version of erythropoietin, which stimulates the production of red blood cells. Aranesp has been used since its approval by the U.S. Food and Drug Administration (FDA) in 2001 to treat patients with anemia, as well as chronic renal failure. It has been frequently prescribed to individuals suffering anemia as a byproduct of chemotherapy.
The FDA has required black box warnings on all sales of Darbepoetin alfa in the United States, citing a number of potential adverse health risks, including:
- Myocardial infarction, or heart attack, as well as congestive heart failure
Hypertension (high blood pressure), with increased risk of stroke
- Venous thromboembolism
- Thrombosis of vascular access
- Tumor progression or recurrence
If you experienced side effects after being prescribed Aranesp, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.
Defective Drugs & Medical Devices Topics
Happy New Year 2020
Wishing you happy holidays and a wonderful new year. Best wishes from everyone at GetLegal.Read More 23 Dec 2019, Monday
Slip-and-fall Claims on Commercial Property
Your Best Chance of Recovery When You Are Hurt on Business Premises As a general rule, all property…Read More 02 Dec 2019, Monday
Thanksgiving—A Time of Gratitude
Life is about connection… about the power of relationships to help us find and nurture our best se…Read More 27 Nov 2019, Wednesday